-+ 0.00%
-+ 0.00%
-+ 0.00%

Biodexa Pharmaceuticals Announces Phase 3 Study Of eRapa In FAP Is In The Final Stages Of Implementation. Will Be a Double-Blind Placebo-Controlled Trial In 168 Patients,

Benzinga·05/30/2025 12:51:08
Listen to the news

The Phase 3 study of eRapa in FAP is in the final stages of implementation. It will be a double-blind placebo-controlled trial in 168 patients, randomized 2:1 drug / placebo. It is expected the study will be conducted in approximately 30 clinical sites across the US and Europe. The US component of the study will be conducted by LumaBridge, based in San Antonio, Texas and the European component will be conducted by Precision for Medicine LLC. All planned US sites and the majority of European sites have been identified. Recruitment is expected to begin in the next few weeks.